CSI Laboratories, a private national cancer diagnostics laboratory, has received approval from the Children's Oncology Group (COG) to begin analyzing pediatric cytogenetic cases. The Children's Oncology Group is the world's largest children's cancer research organization and includes more than 210 member hospitals with over 6,500 medical professionals.
"CSI is honored to gain the approval of the Children's Oncology Group for our cytogenetic laboratory. An approval by COG is reserved for the limited number of laboratories who exceed their high standards. This recognition is yet another example of our commitment to provide the highest-quality diagnostic services to our clients and patients," said Dr. Lawrence Hertzberg, CSI Laboratories' Medical Director.
CSI Laboratories' cytogenetic laboratory is directed by Dr. Theresa Brown, who has over twenty years of experience in diagnostic cytogenetics. CSI received COG approval by showing a cytogenetic abnormality rate of 73% on submitted pediatric acute lymphoblastic leukemia cases. This far exceeded the required rate of 55%.
In addition to cancer cytogenetic testing, the genetics group at CSI Laboratories offers a complete menu of fluorescence in-situ hybridization assays for the diagnosis and monitoring of hematopoietic and solid-tumor diseases.
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery